LivaNova(US:LIVN)2024-07-31 15:30Financial Performance - Net revenue increased by 9.6% on a constant-currency basis to $318.6 million[1,4] - Excluding the ACS segment wind down, net revenue increased 10.8% on a constant-currency basis[94,73] - The company is targeting $95 - $115 million of adjusted free cash flow for full-year 2024[11] - LTM adjusted free cash flow was $139.9 million with an LTM adjusted free cash flow conversion ratio of 79%[11] Segment Performance - Cardiopulmonary revenue increased 14.5% to $173.7 million, driven by strong demand for consumables and Essenz sales[80,81] - Neuromodulation revenue increased 7.8% to $142.9 million, with growth across all regions[83,84] - United States Cardiopulmonary revenue increased 29.7% to $64.9 million[77] - United States Neuromodulation revenue increased 7.3% to $111.7 million[77] Guidance - The company is raising full-year guidance for net revenue growth to 7-8% and net revenue growth, excluding ACS, to 9-10%[31] - The company is raising full-year guidance for adjusted diluted EPS to $3.10 - $3.20[31]